1
|
Kunkler IH, Fielding RG, Brebner J, Prescott R, Maclean JR, Cairns J, Chetty U, Neades G, Walls A, Bowman A, Dixon JM, Gardner T, Smith M, MacCoubrey J, Lee AJ, Swann S, Mcnab M, Wilson J, Nawroz I. A comprehensive approach for evaluating telemedicine-delivered multidisciplinary breast cancer meetings in southern Scotland. J Telemed Telecare 2016; 11 Suppl 1:71-73. [PMID: 16124136 DOI: 10.1258/1357633054461804] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Multidisciplinary team (MDT) meetings for decisions on cancer management are a cornerstone of UK cancer policy. We have proposed a comprehensive methodology to assess the clinical and economic effectiveness of telemedicine in this setting, which is being tested in a randomized breast cancer trial. Pre- and post-telemedicine assessment includes attitudes to and expectations of telemedicine, based on semistructured interviews. The communication content of videotapes of the MDT meeting is being scored using Borgatta's revised Interaction Process Analysis System. The technical performance of the telemedicine equipment is reported on a standardized pro forma. A short questionnaire captures key elements of professional satisfaction for each patient discussion (consensus on future management, confidence in and sharing of decision), added value of linkage, group atmosphere, overall conduct of the meeting and compliance with SIGN guidelines. A cost-minimization analysis will be used for economic assessment.
Collapse
Affiliation(s)
- I H Kunkler
- University Department of Clinical Oncology and Edinburgh Breast Unit, Western General Hospital, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Fielding RG, Macnab M, Swann S, Kunkler IH, Brebner J, Prescott RJ, Maclean JR, Chetty U, Neades G, Walls A, Bowman A, Dixon JM, Gardner T, Smith M, Lee MJ, Lee RJ. Attitudes of breast cancer professionals to conventional and telemedicine-delivered multidisciplinary breast meetings. J Telemed Telecare 2016; 11 Suppl 2:S29-34. [PMID: 16447355 DOI: 10.1258/135763305775124812] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We surveyed the attitudes of breast cancer professionals to standard face-to-face and future telemedicine-delivered breast multidisciplinary team (MDT) meetings. Interviews, which included the Group Behaviour Inventory, were conducted face-to-face (n = 19) or by telephone (n = 26). The mean total score on the Group Behaviour Inventory was 96 (SD 19) for 33 respondents, which indicated satisfaction with standard MDT meetings, irrespective of role and base hospital. Positive attitudes to videoconferencing were more common among participants with previous experience of telemedicine (Spearman's rank correlation 0.26, P = 0.91). Common themes emerging from the interviews about telemedicine-delivered MDTs included group leadership, meeting efficiency, group interaction, group atmosphere and technical quality of communication. Most participants were satisfied with standard breast MDTs. Nurses and allied health professionals were least supportive of telemedicine.
Collapse
|
3
|
Bing AU, Kerr GR, Jack W, Chetty U, Williams LJ, Rodger A, Dixon JM. Pooled long-term outcomes from two randomized trials of axillary node sampling with axillary radiotherapy versus axillary node clearance in patients with operable node-positive breast cancer. Br J Surg 2016; 103:81-7. [PMID: 26768099 DOI: 10.1002/bjs.9952] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 04/20/2015] [Accepted: 08/25/2015] [Indexed: 11/06/2022]
Abstract
BACKGROUND The aim was to determine long-term overall, breast cancer-specific and metastasis-free survival as well as axillary relapse rate from a pooled analysis of two randomized trials in women with operable breast cancer. These trials compared axillary node sampling (ANS), combined with axillary radiotherapy (AXRT) if the sampled nodes were involved, with axillary node clearance (ANC). METHODS Data from two clinical trials at the Edinburgh Breast Unit that randomized patients between 1980 and 1995 were pooled. Long-term survival was analysed using Kaplan-Meier curves and Cox regression, with separate analyses for patients with node-positive (ANS + AXRT versus ANC) and node-negative (ANS versus ANC) disease. RESULTS Of 855 women randomized, 799 were included in the present analysis after a median follow-up of 19·4 years. Some 301 patients (37·7 per cent) had node-positive disease. There was no evidence of a breast cancer survival advantage for ANS versus ANC in patients with node-negative disease (hazard ratio (HR) 0·88, 95 per cent c.i. 0·58 to 1·34; P = 0·557), or for ANS + AXRT versus ANC in those with node-positive breast cancer (HR 1·07, 0·77 to 1·50; P = 0·688). There was no metastasis-free survival advantage for ANS versus ANC in patients with node-negative tumours (HR 1·03, 0·70 to 1·51; P = 0·877), or ANS + AXRT versus ANC in those with node-positive disease (HR 1·03, 0·75 to 1·43; P = 0·847). Node-negative patients who underwent ANS had a higher risk of axillary recurrence than those who had ANC (HR 3·53, 1·29 to 9·63; P = 0·014). Similarly, among women with node-positive tumours, the risk of axillary recurrence was greater after ANS + AXRT than ANC (HR 2·64, 1·00 to 6·95; P = 0·049). CONCLUSION Despite a higher rate of axillary recurrence with ANS combined with radiotherapy to the axilla, ANC did not improve overall, breast cancer-specific or metastasis-free survival. Axillary recurrence is thus not a satisfactory endpoint when comparing axillary treatments.
Collapse
Affiliation(s)
- A U Bing
- Edinburgh Breast Unit, University of Edinburgh, Edinburgh, UK
| | - G R Kerr
- Oncology Department, Western General Hospital, Edinburgh, UK
| | - W Jack
- Edinburgh Breast Unit, University of Edinburgh, Edinburgh, UK
| | - U Chetty
- Edinburgh Breast Unit, University of Edinburgh, Edinburgh, UK
| | - L J Williams
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
| | - A Rodger
- Edinburgh Breast Unit, University of Edinburgh, Edinburgh, UK
| | - J M Dixon
- Edinburgh Breast Unit, University of Edinburgh, Edinburgh, UK.,Breast Cancer Now Research Unit, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
4
|
Bing A, Kerr G, Jack W, Williams L, Roger A, Chetty U, Dixon M. 14. Pooled long term outcomes from two randomised trials of axillary node sampling with axillary radiotherapy if node positive versus axillary node clearance in patients with operable breast cancer. Eur J Surg Oncol 2015. [DOI: 10.1016/j.ejso.2015.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Blamey RW, Bates T, Chetty U, Duffy SW, Ellis IO, George D, Mallon E, Mitchell MJ, Monypenny I, Morgan DAL, Macmillan RD, Patnick J, Pinder SE. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 2013; 49:2294-302. [PMID: 23523089 DOI: 10.1016/j.ejca.2013.02.031] [Citation(s) in RCA: 142] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2011] [Revised: 01/31/2013] [Accepted: 02/25/2013] [Indexed: 11/26/2022]
Abstract
BACKGROUND The incidence of local recurrence (LR) after conservative surgery for early breast cancer without adjuvant therapy is unacceptably high even with favourable tumours. The aim of this study was to examine the effect of adjuvant therapies in tumours with excellent prognostic features. METHODS Patients with primary invasive breast cancer <2 cm diameter, grade 1 or good prognosis special type, and node negative, treated by wide local excision (WLE) with clear margins were randomised into a 2 × 2 clinical trial of factorial design with or without radiotherapy and with or without tamoxifen. Trial entry was allowed to either comparison or both. FINDINGS The actuarial breast cancer specific survival in 1135 randomised patients at 10 years was 96%. Analysis by intention to treat showed that LR after WLE was reduced in patients randomised to radiotherapy (RT) (HR 0.37, CI 0.22-0.61 p<0.001) and to tamoxifen (HR 0.33, CI 0.15 - 0.70 p<0.004). Actuarial analysis of patients entered into the four-way randomisation showed that LR after WLE alone was 1.9% per annum (PA) versus 0.7% with RT alone and 0.8% with tamoxifen alone. No patient randomised to both adjuvant treatments developed LR. Analysis by treatment received showed LR at 2.2%PA for surgery alone versus 0.8% for either adjuvant radiotherapy or tamoxifen and 0.2% for both treatments. CONCLUSIONS Even in these patients with tumours of excellent prognosis, LR after conservative surgery without adjuvant therapy was still very high. This was reduced to a similar extent by either radiotherapy or tamoxifen but to a greater extent by the receipt of both treatments.
Collapse
Affiliation(s)
- R W Blamey
- Nottingham City Hospital, Hucknall Rd., Nottingham NG5 1PB, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Spears M, Pedraza J, Thomas J, Kerr G, Kerr W, Campbell F, McKay L, Kunkler I, Cameron D, Chetty U, Bartlett J. Expression Levels of Co-Regulators in Early Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The p160 (SRC) family of estrogen receptor (ER) co-activators have important implications in tamoxifen resistance. The SRC family play a central role in ER mediated transcription. There are three family members; SRC-1, SRC-2 and AIB1. AIB1 is amplified in 5-10% of human breast cancers. SRC-1 expression is associated with HER2 expression, increased risk of recurrence and insensitivity to endocrine treatment. Co-factors interact with the ER and basal transcriptional machine to activate or repress ER-mediated transcription. To investigate the role of ER and its co-factors in breast cancer we have carried out quantitative RT-PCR (qRT-PCR) to measure the relative expression of ERa and its co-factors.Methods: In this study we examined patients which were untreated or treated with chemotherapy or hormonal therapy following breast conservation surgery. RNA was extracted from 340 early breast cancer specimens from the Edinburgh Breast Conserving Surgery cohort (BCS). The BCS is a fully documented consectutive cohort of breast cancers treated by conservation surgery, axillary node sampling or clearance, and whole breast radiotherapy between 1981-1998. Clinico-pathological features and complete follow up (duration >10 years) is available for this cohort. qRT-PCR was carried out using primers for ER, SRC-1, SRC-2, AIB1, NCoR1 and SMRT.Results: This study demonstrated SRC-1 expression to be negatively correlated with both SRC-2 and AIB1 expression. SRC-1 expression was also negatively correlated with the co-repressors NCoR1 and SMRT expression. There was a strong correlation between the co-repressors, NCoR1 and SMRT and the co-activators SRC-2 and AIB1. Relapse-free survival (RFS) was estimated using Kaplan-Meier curves. Patients who had high expression of all three co-activators had reduced relapse-free survival (HR: 2.15 95%C.I. 1.175-3.921, p=0.01). No significant association was noted with overall survival. Exploratory subgroup analysis was under powered and showed no significant association with outcome.Conclusion: In conclusion, our study of expression levels of ER and its cofactors by quantitative RT-PCR in breast cancer samples revealed a correlation between the co-factors and co-repressors. These findings would suggest that ER and cofactors may play a synergistic role in the development and progression of breast cancer.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2127.
Collapse
Affiliation(s)
- M. Spears
- 1University of Edinburgh, United Kingdom
| | - J. Pedraza
- 1University of Edinburgh, United Kingdom
| | - J. Thomas
- 2Western General Hospital, United Kingdom
| | - G. Kerr
- 2Western General Hospital, United Kingdom
| | - W. Kerr
- 2Western General Hospital, United Kingdom
| | | | - L. McKay
- 1University of Edinburgh, United Kingdom
| | - I. Kunkler
- 2Western General Hospital, United Kingdom
| | | | - U. Chetty
- 2Western General Hospital, United Kingdom
| | | |
Collapse
|
7
|
Spears M, Cunningham C, Thomas J, Kerr G, Jack W, Campbell F, McKay L, Kunkler I, Cameron D, Chetty U, Bartlett J. The Expression of Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Early Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The insulin-like growth factor-1 receptor (IGF-1R) is expressed in normal breast epithelial cells and breast carcinomas. A number of studies have examined the over-expression of IGF-1R in breast cancer with the range of between 39% to 93%. However, many of these studies were carried out using ELISAs, radioimmunoassay with small patient cohorts. Phosphorylation of IGF-1R results in the activation of the MAPK and PI3K/Akt pathway. Activation of the PI3K/Akt pathway under the influence of IGF-1R plays an important role in maintaining the proliferation of breast cancer cells that are resistant to gefitnib, trastuzumab or chemoradiotherapy in vitro and in vivo. In the present study, we examined the expression of IGF-1R in early breast cancer and investigated the clinicopathological implications using immunohistochemistry and FISH.Methods: TMAs from a consecutive series (1981-98) of 1,812 women managed by wide local excision and postoperative radiotherapy (45Gy in 20-25 fractions) were collected following appropriate ethical review. Of 1686 cases stained, 198 received no adjuvant hormonal or chemotherapy, 1106 received tamoxifen only as adjuvant therapy and 144 received a combination of hormonal and chemotherapy. Median age at diagnosis was 56, 72% were post-menopausal, 23.9% node positive, median size was 1.5 cm. Samples were stained, using triplicate 0.6mm2 TMA cores for IGF-1R.Results: FISH for IGF1R gene amplification was successful in 343/408 cases (84%). Only 7 cases of IGF1R amplification were observed (2%). IGF1R expression was successfully evaluated in 1597 of 1686 (94.7%) cases. High levels of IGF-1R expression was weakly associated with tumour ER-a (correlation coefficient, 0.108; p=2.2 x 10-5) and PgR levels (correlation coefficient 0.162; p=1.86x10-10) and inversely correlated with EGFR expression (correlation coefficient -0.189; p=6.33x10-6). No association was noted between IGF1R expression and other molecular or clinical markers, such as tumour size. There was a trend for over-expression of IGF-1R to link with increased distant relapse free survival, particularly in ER positive breast cancers. This trend is time dependent, such that no difference in outcome is observed at 15 years.Conclusions: We have demonstrated in a large cohort of patients that IGF-1R gene amplification is a rare event, and over-expression is weakly associated with good prognostic features (ERa and PgR, lack of EGFR and better outcome).
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2128.
Collapse
Affiliation(s)
- M. Spears
- 1University of Edinburgh, United Kingdom
| | | | - J. Thomas
- 2Western General Hospital, United Kingdom
| | - G. Kerr
- 2Western General Hospital, United Kingdom
| | - W. Jack
- 2Western General Hospital, United Kingdom
| | | | - L. McKay
- 1University of Edinburgh, United Kingdom
| | - I. Kunkler
- 2Western General Hospital, United Kingdom
| | | | - U. Chetty
- 2Western General Hospital, United Kingdom
| | | |
Collapse
|
8
|
Bartlett JM, Thomas JS, Chetty U, Seitz RS, Ross DT, Ring BZ, Pedersen HC, Beck RA, Campbell FM, Jack W, Kerr G, McKay L, Kunkler IH. Mammostrat® as a tool to stratify patients at risk of recurrence during endocrine therapy. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3026
Background: Patients with early stage ER+ve breast cancer have excellent prognosis with ca 90% 5 year disease free survival when treated with endocrine therapy. However for patients who relapse during endocrine therapy additional adjuvant therapy options, such as chemotherapy, are indicated. The challenge is to prospectively identify such patients. The Mammostrat® test comprises 5 simple immunohistochemical markers (p53, HTF9C, CEACAM5, NDRG1, SLC7A5) which stratify node negative tamoxifen treated patients into low, moderate and high risk groups. We have now tested the efficacy of this panel in a mixed population of node positive/node negative cases treated in a single centre (Edinburgh Breast Unit) with breast conserving surgery.
 Methods: TMAs from a consecutive series (1981-98) of 1,812 women managed by wide local excision and postoperative radiotherapy (45Gy in 20-25 fractions) were collected following appropriate ethical review. Of 1390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1044 received tamoxifen only as adjuvant therapy and 149 received a combination of hormonal and chemotherapy. Median age at diagnosis was 57, 71% were post-menopausal, 23.9% node positive, median size was 1.5 cm. Samples were stained, using triplicate 0.6mm2 TMA cores and positivity for p53, HTF9C, CEACAM5, NDRG1, SLC7A5 recorded as previously described. Each case was assigned a Mammostrat score and RFS and OS analysed by marker positivity and Mammostrat score.
 Results: Staining for all 5 antibodies was successful in 1174/1390 (84%) of cases. In the primary analysis of 531 N0/ER+ve Tamoxifen only treated patients Mammostrat was significantly associated with relapse free survival (RFS) in univariate (p=0.025) & multivariate proportional hazards analysis (p=0.01, HR=1.3, 95%C.I. 1.08-1.74). PgR, multifocality and menopausal status were significant co-variates (p<0.05, HR 0.89, 2.0 & 0.6 respectively). The Nottingham prognostic index was non-significant. Of the 5 antibodies, only p53 (p=0.04) was independently predictive of survival.
 In a secondary univariate analysis of 781 patients (including N+ve and chemo/tam treated patients) Mammostrat was predictive of RFS & OS (p<0.01) with NDRG1/CEACAM5/p53 also predictive of RFS(p<0.05). However Mammostrat was not independent of nodal status, pathological size, grade or multifocality in a proportional hazards analysis.
 Discussion: In the Edinburgh BCS population Mammostrat was predictive of RFS (both local and distant relapses) in N-ve/ER+ve patients treated with tamoxifen alone irrespective of menopausal status. There was a strong correlation between Mammostrat scores and grade, however, in a multivariate analysis Mammostrat contributed significantly to prognostication along with PgR, multifocality and menopausal status.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3026.
Collapse
Affiliation(s)
- JM Bartlett
- 1 Endocrine Cancer Group, University of Edinburgh, Edinburgh, United Kingdom
| | - JS Thomas
- 2 Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - U Chetty
- 2 Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - RS Seitz
- 3 Applied Genomics Inc, Burlinghame, CA
| | - DT Ross
- 3 Applied Genomics Inc, Burlinghame, CA
| | - BZ Ring
- 3 Applied Genomics Inc, Burlinghame, CA
| | - HC Pedersen
- 1 Endocrine Cancer Group, University of Edinburgh, Edinburgh, United Kingdom
| | - RA Beck
- 3 Applied Genomics Inc, Burlinghame, CA
| | - FM Campbell
- 1 Endocrine Cancer Group, University of Edinburgh, Edinburgh, United Kingdom
| | - W Jack
- 2 Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - G Kerr
- 2 Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | - L McKay
- 1 Endocrine Cancer Group, University of Edinburgh, Edinburgh, United Kingdom
| | - IH Kunkler
- 2 Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom
| | | |
Collapse
|
9
|
Kunkler IH, Chetty U, Jack W, Kerr G, Thomas J, Bartlett JM. Implications from long-term follow-up after breast-conserving therapy for patient selection and duration of follow-up: The Edinburgh experience. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Pedersen H, Ventura R, Faratian D, Chetty U, Dixon J, Jack W, Kerr G, Kunkler I, Bartlett J. Monoclonal antibodies specific for Phospho-4E-BP1 (Thr 70) and phospho-AKT (Ser 473) indicate prognosis in breast cancer. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70350-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Chetty U, Chin PKY, Soon PHS, Jack W, Thomas JSJ. Combination blue dye sentinel lymph node biopsy and axillary node sampling: The Edinburgh experience. Eur J Surg Oncol 2008; 34:13-6. [PMID: 17498913 DOI: 10.1016/j.ejso.2007.02.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2007] [Accepted: 02/15/2007] [Indexed: 11/27/2022] Open
Abstract
AIMS The sentinel node biopsy technique which is being increasingly used to stage breast cancers has limitations regarding not being able to find the blue hot node in about 5% of cases and false negative results in 7% of cases. It has been suggested this is probably due to tumour blocking the lymphatic channels. The four node sampling technique is dependent on the surgeon's ability to find abnormal palpable nodes in the axilla without visual or radioactive signal directions. We have combined the two techniques with the expectation to improve the results. METHOD The study evaluates the combined technique in 434 patients with early breast cancer in a single centre. RESULTS A blue sentinel node was identified in 394 of 434 cases (91.7%), the false negative rate was 2.4%. Thirty six patients had no sentinel node identified. Thirteen of these had positive nodes in the node sample. CONCLUSION Axillary node sampling adds to the accuracy of the sentinel node biopsy using blue dye. Pathological features suggest that the principal cause of false negative sentinel node biopsy is due to blocking of the lymphatic channels by the cancer.
Collapse
Affiliation(s)
- U Chetty
- Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, UK.
| | | | | | | | | |
Collapse
|
12
|
Blamey R, Chetty U, Bates T, Duffy S, Ellis I, George D, Mallon E, Mitchell M, Morgan D, Macmillan R, Patnick J, Pinder S. O-11 Radiotherapy and/or tamoxifen after conserving surgery for breast cancers of excellent prognosis: BASO II TRIAL. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71701-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
13
|
Ellis C, Wild S, Chetty U, Dodd C, Barber M. O-25 Are there associations between deprivation and tumour characteristics and treatment factors in the scan breast cancer database? EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71715-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
14
|
Dodds C, Chetty U, Wilson G, Muir P, Gregor A. Performance in a Scottish cancer network (SCAN) against ASCO/NCCN clinical quality measures for breast and colorectal cancers. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.17001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17001 Performance in a Scottish cancer network (SCAN) against ASCO/NCCN Clinical Quality Measures for breast and colorectal cancer. Background: South East Scotland Cancer Network (SCAN) aims to improve care, treatment, and equity for all cancer patients in the 1.4m population under its care ( www.scan.scot.nhs.uk ). Clinical care is delivered by multidisciplinary teams in 7 hospitals and one regional cancer centre. Key function of the network is prospective audit collecting externally validated information on evidence-based performance indicators. Method: Cohorts of 624 breast and 359 colorectal cancer patients diagnosed over a 12-month period in Lothian have been analysed against the ASCO/NCCN measures. Conclusions: SE Scotland Breast and Colorectal services compare favourably with the ASCO/NCCN standards of care on most measures. Use of radiotherapy in rectal cancer conforms to Scottish guidelines. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Dodds
- S E Scotland Cancer Network, Edinburgh, United Kingdom
| | - U. Chetty
- S E Scotland Cancer Network, Edinburgh, United Kingdom
| | - G. Wilson
- S E Scotland Cancer Network, Edinburgh, United Kingdom
| | - P. Muir
- S E Scotland Cancer Network, Edinburgh, United Kingdom
| | - A. Gregor
- S E Scotland Cancer Network, Edinburgh, United Kingdom
| |
Collapse
|
15
|
Carmichael AR, McIntyre M, Chetty U. Malignant melanoma in accessory nipple in a male. J Coll Physicians Surg Pak 2006; 16:799-800. [PMID: 17125645 DOI: 12.2006/jcpsp.799800] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
16
|
Dodds C, Cameron, Jack W, Kunkler I, Chetty U. Improving equity of access to treatment for breast cancer patients in south east Scotland: an audit of time from final surgery to radiotherapy. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80214-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
17
|
|
18
|
Johnston D, Macpherson DS, Barrie WW, Eaton AC, Brossy JJ, Vessey MP, Kalache A, Chetty U, Wang CC, Forrest APM, Roberts MM, White CM, Price JJ, Findlay JM, Gillespie G, Gunn A, Fraser I, Quick C, Johnstone M, Tutt GO, Buysschaert M, Kestens PJ, Lambotte L, Marchand E, Lambert AE. Correspondence. Br J Surg 2005. [DOI: 10.1002/bjs.1800680824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- David Johnston
- University Department of Surgery, The General Infirmary, Leeds LS1 3EX
| | - D S Macpherson
- Department of Surgery, Leicester General Hospital, Leicester LE5 4PW
| | - W W Barrie
- Department of Surgery, Leicester General Hospital, Leicester LE5 4PW
| | - A C Eaton
- Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PD
| | - J-J Brossy
- Department of Surgery, Somerset Hospital, 8051 Cape, South Africa
| | - M P Vessey
- Department of Community Medicine, and General Practice, University of Oxford, Oxford OX1 3QN
| | - A Kalache
- Department of Community Medicine, and General Practice, University of Oxford, Oxford OX1 3QN
| | - U Chetty
- University Department of Clinical Surgery, The Royal Infirmary, Edinburgh, EH3 9YW
| | - C C Wang
- University Department of Clinical Surgery, The Royal Infirmary, Edinburgh, EH3 9YW
| | - A P M Forrest
- University Department of Clinical Surgery, The Royal Infirmary, Edinburgh, EH3 9YW
| | - M M Roberts
- University Department of Clinical Surgery, The Royal Infirmary, Edinburgh, EH3 9YW
| | - C M White
- 4 Hall Close, Bramhope, Leeds LS16 9JQ
| | - J J Price
- 4 Hall Close, Bramhope, Leeds LS16 9JQ
| | | | | | - A Gunn
- Ashington Hospital, West View, Ashington, Northumberland NE63 0SA
| | - Ian Fraser
- Department of Surgery, Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX
| | - Clive Quick
- Department of Surgery, Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX
| | - Michael Johnstone
- Department of Surgery, Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX
| | - George O Tutt
- Henson, Wise and Otteman, Surgical Associates PC, 1015 Robertson, Fort Collins, Colorado 80524, USA
| | - M Buysschaert
- Departments of Internal Medicine and Surgery, University Hospital St Luc, B 1200 Brussels, Belgium
| | - P J Kestens
- Departments of Internal Medicine and Surgery, University Hospital St Luc, B 1200 Brussels, Belgium
| | - L Lambotte
- Departments of Internal Medicine and Surgery, University Hospital St Luc, B 1200 Brussels, Belgium
| | - E Marchand
- Departments of Internal Medicine and Surgery, University Hospital St Luc, B 1200 Brussels, Belgium
| | - A E Lambert
- Departments of Internal Medicine and Surgery, University Hospital St Luc, B 1200 Brussels, Belgium
| |
Collapse
|
19
|
Chetty U. Contemporary issues in clinical oncology. Breast cancer. Richard Margolese. 240 × 165 mm. Pp. 300 + xvi. Illustrated. 1983. Edinburgh: Churchill Livingstone. £28.00. Br J Surg 2005. [DOI: 10.1002/bjs.1800710744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
20
|
Goyal A, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L, Kissin M, Sibbering M. Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for breast cancer. Eur J Cancer 2005; 41:238-43. [PMID: 15661548 DOI: 10.1016/j.ejca.2004.05.008] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2004] [Revised: 05/10/2004] [Accepted: 05/11/2004] [Indexed: 11/18/2022]
Abstract
Sentinel node biopsy (SNB) is rapidly emerging as the preferred technique for nodal staging in breast cancer. When radioactive colloid is used, a preoperative lymphoscintiscan is obtained to ease sentinel lymph node (SN) identification. This study evaluates whether preoperative lymphoscintigraphy adds diagnostic accuracy to offset the additional time and cost required. 823 breast cancer patients underwent SNB based on lymphoscintigraphy, intraoperative gamma probe detection, and blue dye mapping using 99 mTc-nanocolloid and Patent Blue V injected peritumourally. The SNB was followed by standard axillary treatment at the same operation. Preoperative lymphoscintigraphy was performed around 3 h after the radioisotope injection. Preoperative lymphoscintigraphy revealed SNs in 593 (72%) of the 823 patients imaged. SN visualisation on lymphoscintigraphy was less successful in large tumours and tumours involving the upper outer quadrant of the breast (P=0.046, P<0.001, respectively). Lymphoscintigraphy showed internal mammary sentinel nodes in 9% (62/707) patients. The SN was identified intraoperatively in 98% (581) patients who had SN visualised on preoperative lymphoscintigraphy, with a false-negative rate of 7%. In patients who did not have SN visualised on preoperative lymphoscintigraphy, the SN was identified at operation in 90% (204) patients, with a false-negative rate of 7%. The SN identification rate was significantly higher in patients with SN visualised on preoperative lymphoscintigraphy (P<0.001). SN identification rate intraoperatively using the gamma probe was significantly higher in the SN visualised group compared with the SN non-visualised group (95% vs. 68%; chi square (1 degrees of freedom (df)) P<0.001. There was no statistically significant difference in the false-negative rate and the operative time between the two groups. A mean of 2.3 (standard deviation (SD) 1.3) SNs per patient were removed in patients with SN visualised on preoperative lymphoscintigraphy compared with 1.8 (SD 1.2) in patients with no SN visualised on lymphoscintigraphy (P<0.001). Although SN visualisation on preoperative lymphoscintigraphy significantly improved the intraoperative SN localisation rate, SN was successfully identified in 90% of patients with no SN visualisation on lymphoscintigraphy. Given the time and cost required to perform routine preoperative lymphoscintigraphy, these data suggest that it may not be necessary in all cases. It may be valuable for surgeons in the learning phase to shorten the learning curve and in patients who have increased risk of intraoperative failed localisation (obese or old patients). A negative preoperative lymphoscintiscan predicts the inability to localise with the hand-held gamma probe. Therefore, if the SN is not visualised on lymphoscintigraphy then the addition of intraoperative blue dye is recommended to increase the likelihood of SN identification.
Collapse
Affiliation(s)
- Amit Goyal
- Department of Surgery, University of Wales College of Medicine, Cardiff, CF14 4XN, UK
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Goyal A, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L, Kissin M, Sibbering M. Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur J Surg Oncol 2004; 30:475-9. [PMID: 15135472 DOI: 10.1016/j.ejso.2004.02.009] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2004] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Multifocal or multicentric breast cancer has been suggested as a contraindication for sentinel node biopsy (SNB). However, recent studies have demonstrated that all quadrants of the breast drain through common afferent channels to a common axillary sentinel node. This should mean that the presence of multifocal tumour should not affect the lymphatic drainage. The purpose of this study was to evaluate the feasibility and accuracy of SNB in patients with multifocal breast cancer using a peritumoural injection technique for sentinel lymph node (SN) mapping. METHODS In the ALMANAC multicentre trial validation phase, we took SNB samples from 842 patients with node negative, invasive breast cancer with use of a blue dye and radiolabelled colloid mapping technique at the peritumoural injection site. All patients underwent standard axillary treatment after SNB. Seventy-five of the 842 patients had multifocal lesions on final histopathologic examination. The following analysis is focused on patients with multifocal lesions. RESULTS A mean number of 2.4 SNs were identified in 71 of 75 patients (identification rate: 94.7%). Thirty-one patients had a positive SN, 40 a negative SN. Standard axillary treatment confirmed the SN to be negative in 37 of 40 patients, whereas three patients revealed positive non-sentinel lymph nodes (false-negative rate: 8.8%). Overall SN biopsy accurately predicted axillary lymph node status in 68 of 71 patients (95.8%). CONCLUSION SNB accurately staged the axilla in multifocal breast cancer and may become an alternative to complete axillary lymph node dissection in node negative patients with multifocal breast cancer.
Collapse
Affiliation(s)
- A Goyal
- Department of Surgery, University of Wales College of Medicine, Cardiff CF14 4XN, UK
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Goyal A, Horgan K, Kissin M, Yiangou C, Sibbering M, Lansdown M, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L, Kissin M. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004; 30:480-3. [PMID: 15135473 DOI: 10.1016/j.ejso.2004.02.006] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2004] [Indexed: 12/18/2022] Open
Abstract
The concept of sentinel node biopsy has been validated for female breast cancer patients whereas, ALND remains the standard of care for male breast cancer patients with similar tumours. We evaluated the results of SLN biopsy in male breast cancer patients with clinically negative axillae. This study included all male breast cancer patients who underwent SLN biopsy between February 1998 and October 2003. All patients had negative axillae on clinical examination. All patients underwent pre-operative lymphoscintigraphy. SLN biopsy was performed using a combination of Patent blue V and 99mTc-radiolabelled colloidal albumin injected peritumourally. Nine patients, 26-79 years of age, were included in the study. Pre-operative lymphoscinitgraphy identified SLNs in all patients. Intraoperatively, SLNs were successfully localised in all patients. The mean number of SLNs encountered was 2.4. Five patients had a positive SLN, four a negative SLN. Five patients (one with a negative SLN, four with a positive SLN) had been elected pre-operatively to undergo ALND regardless of findings on SLN biopsy. ALND confirmed the SLN to be negative in one patient (false-negative rate: 0%) and three of the four patients with positive SLN(s) had additional positive nodes in the axilla. SLN biopsy accurately predicted axillary lymph node status in these five patients. These findings compare favourably with findings reported in the literature regarding SLN biopsy in female breast cancer patients. SLN biopsy accurately staged the axilla in male breast cancer patients and should be considered for axillary staging in male breast cancer patients with clinically negative axillae.
Collapse
Affiliation(s)
- A Goyal
- Department of Surgery, University of Wales College of Medicine, Cardiff, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
AIMS Frozen section histology of lymph nodes intraoperatively is associated with a false negative rate of twenty-five per cent. Imprint cytology is reported to have greater accuracy than frozen section. Accurate intraoperative examination of lymph nodes could help to prevent some patients from having a second axillary operation in breast cancer. This study assesses the sensitivity of imprint cytology to lymph node metastases using two different staining techniques. METHODS Imprint cytology of 238 freshly excised axillary lymph nodes in 53 patients with stage T1-2, N0, M0 breast cancer was performed. Imprints were stained using toluidine blue dye and anti-pancytokeratin immunoglobulin to compare the two staining methods. A consultant histopathologist blinded to the routine histology results examined each set of imprints. A non-pathologist also examined each set of imprints to determine whether a technician could be used to screen slides in order to decrease the workload of the pathologist. RESULTS Sensitivity was 82% with toluidine blue and 36.4% with anti-pancytokeratin immunoglobulin. Positive predictive values were 100% and 57% respectively for toluidine blue and anti-pancytokeratin. The false-negative rate was 18% for toluidine blue and 63.6% for anti-pancytokeratin antibody when examined by a consultant histopathologist. CONCLUSIONS Imprint cytology using toluidine blue is as sensitive as frozen section in the detection of axillary lymph node metastases. A positive result may be acted upon with acceptable safety. Immunohistochemistry using antibody to pancytokeratin did not improve imprint sensitivity in this study. Imprint cytology could help to prevent a second operation in 80% of breast cancer patients with positive lymph nodes.
Collapse
Affiliation(s)
- P A Lambah
- Edinburgh Breast Unit, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
| | | | | | | |
Collapse
|
24
|
Abstract
AIMS There are no uniformly agreed guidelines regarding the treatment of local breast cancer in patients who have stable metastatic disease. The aim of this study was to define the role of breast surgery in the management of stage IV disease by reviewing the clinical outcome in patients with stage IV disease submitted to surgery in a regional breast cancer unit. METHODS All patients who underwent breast surgery from 1993 to 1999 and had known metastatic disease or who were diagnosed with metastases within one month of surgery were identified and their clinical outcome was studied using death and local recurrence as end points. RESULTS Median survival after breast surgery was 23 months. Ten of the 20 patients were alive with no local disease at 20 months mean follow-up. Three of 10 patients who died developed local recurrence and had local disease at the time of death. CONCLUSION The local surgery does have a role in controlling the primary cancer and controlling local symptoms in a selected group of patients with stable metastatic disease.
Collapse
Affiliation(s)
- A R Carmichael
- Edinburgh Breast Unit, Western General Hospital, Edinburgh, Scotland, UK.
| | | | | | | |
Collapse
|
25
|
Affiliation(s)
- U Chetty
- Edinburgh Breast Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
| |
Collapse
|
26
|
Hawkins RA, Tesdale AL, Prescott RJ, Forster T, McIntyre MA, Baker P, Jack WJL, Chetty U, Dixon JM, Killen ME, Hulme MJ, Miller WR. Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index. Br J Cancer 2002; 87:8-14. [PMID: 12085248 PMCID: PMC2364292 DOI: 10.1038/sj.bjc.6600335] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2001] [Revised: 03/19/2002] [Accepted: 04/08/2002] [Indexed: 11/09/2022] Open
Abstract
In 1990, 215 patients with operable breast cancer were entered into a prospective study of the prognostic significance of five biochemical markers and 15 other factors (pathological/chronological/patient). After a median follow-up of 6.6 years, there were 77 recurrences and 77 deaths (59 breast cancer-related). By univariate analysis, patient outcome related significantly to 13 factors. By multivariate analysis, the most important of nine independent factors were: number of nodes involved, steroid receptors (for oestrogen or progestogen), age, clinical or pathological tumour size and grade. Receptors and grade exerted their influence only in the first 3 years. Progestogen receptors (immunohistochemical) and oestrogen receptors (biochemical) were of similar prognostic significance. The two receptors were correlated (r=+0.50, P=0.001) and displaced each other from the analytical model but some evidence for the additivity of their prognostic values was seen when their levels were discordant.
Collapse
Affiliation(s)
- R A Hawkins
- University Department of Surgery, Royal Infirmary NHS Trust, Edinburgh EH3 9YW, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Chetty U, Dillon P, Prescott R. The history of breast cysts is not associated with the diagnosis of breast cancer. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80145-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
|
29
|
McFadyen IJ, Chetty U, Setchell KD, Zimmer-Nechemias L, Stanley E, Miller WR. A randomized double blind-cross over trial of soya protein for the treatment of cyclical breast pain. Breast 2000; 9:271-6. [PMID: 14732177 DOI: 10.1054/brst.1999.0149] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Twenty patients with cyclical breast pain were enrolled in a double-blind cross-over trial in which either a soy protein drink or a flavoured cow's milk was taken orally each day for 3 months before crossing over to the alternate drink for a further 3 months. Records of pain scores were taken throughout the study. Blood was also taken before and after 3 and 6 months for the measurement of phytoestrogents to assess compliance. Two women withdrew from the study at the outset leaving 18 evaluable patients who completed the study. Of these 10 (56%) felt that soy protein improved breast pain (two of whom received soy as first treatment) and two (11%) felt that cow's milk alleviated symptoms (one receiving this as first preparation) and the remaining six (33%) experienced no relief of pain with either dietary preparation. Blood levels of diadzein and genistein were elevated after the ingestion of soy protein in only 13 patients (seven of whom felt that soy improved their breast pain); in the remaining five patients (three of whom suggested that soy protein improved breast pain) phytoestrogen levels were no higher than pretreatment values. Although the ingestion of soy protein may be associated with relief of breast pain, these results illustrate the problem of non-specific effects in studies of mastalgia in that 1) cow's milk also relieved breast pain in some patients and 2) that the benefits of soy protein were not always associated with evidence of elevated circulating levels of phyto-estrogens, indicating the difficulty of compliance in dietary intervention studies using soy foods.
Collapse
Affiliation(s)
- I J McFadyen
- Longmore Breast Unit, Western General Hospital, Edinburg, UK
| | | | | | | | | | | |
Collapse
|
30
|
Chetty U, Jack W, Prescott RJ, Tyler C, Rodger A. Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial. Edinburgh Breast Unit. Br J Surg 2000; 87:163-9. [PMID: 10671921 DOI: 10.1046/j.1365-2168.2000.01345.x] [Citation(s) in RCA: 110] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND In the treatment of operable breast cancer by breast conservation, the extent of axillary dissection, the need for radiotherapy to the axilla and the morbidity associated with these procedures have not been assessed adequately. METHODS Patients with operable breast cancer were randomized to have level III axillary node clearance (232 patients) or axillary node sample (234 patients). Radiotherapy to the axilla was given selectively. Radiotherapy was not given to those who had an axillary clearance. In the early part of the study all patients who had node sample were treated by radiotherapy (54 patients); subsequently this was modified to include only those who were node positive. The morbidity to the shoulder and arm was assessed before and after operation by measuring upper limb volume and circumference, and combined glenohumeral and scapular movement and muscle power. RESULTS Comparing the two surgical policies, no difference was found in local (axillary clearance 14 versus sample 15), axillary (eight versus seven) or distant (29 versus 29) recurrence. There was no statistically significant difference in 5-year survival rate (clearance 82.1 versus sample 88.6 per cent). Morbidity was least in those who had a node sample and no radiotherapy to the axilla. Radiotherapy to the axilla in patients who had a node sample resulted in a significant reduction in range of movement of the shoulder, e.g. mean(s.e.) 2.2(0.6) cm reduction in lateral rotation at 3 years. Surgical axillary clearance was associated with significant lymphoedema of the upper limb, e.g. 4.1(0.7) per cent increase in arm volume at 3 years. CONCLUSION A selective policy for the management of the axilla is associated with no increase in axillary recurrence or mortality rate compared with routine axillary node clearance. Patients who are node negative after axillary sample can avoid radiotherapy or axillary clearance.
Collapse
Affiliation(s)
- U Chetty
- Correspondence to: Mr U. Chetty, Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, UK
| | | | | | | | | |
Collapse
|
31
|
Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, Hunter JA. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140:249-54. [PMID: 10233217 DOI: 10.1046/j.1365-2133.1999.02657.x] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
From the Scottish Melanoma Group database for south-east Scotland we evaluated 5-year follow-up in patients with cutaneous malignant melanoma excised between 1979 and 1994 and devised an 'evidence-based' review protocol. Of the 1568 with stage I melanoma, 293 (19%) developed a recurrence, 32 had a second primary melanoma and 97 had an in-situ melanoma. The disease-free interval shortened progressively with increasing tumour thickness. Overall, 80% of recurrences were within the first 3 years, but a few patients (< 8%) had recurrences 5 or 10 years after the initial surgery. In-situ melanomas did not recur. Almost half (47%) the recurrences were noted first by the patient, and only 26% were detected first at a follow-up clinic. One hundred and thirty-nine patients (89%) were still under review when their recurrences were detected, and 102 (65%) had been seen within the previous 3 months. Questionnaires were completed by 120 patients: sun protection and avoidance, and mole examination were more likely after melanoma excision. We recommend 3-monthly review of patients with invasive lesions for the first 3 years. Thereafter, those with lesions >/= 1.0 mm need two further annual reviews. Patients with in-situ lesions should be reviewed once, to confirm adequate excision (0.5 cm margins) and to give appropriate education. Surveillance beyond 5 years is only justified if there are special risk factors.
Collapse
Affiliation(s)
- T J Dicker
- University Department of Dermatology, The Royal Infirmary of Edinburgh NHS Trust, UK
| | | | | | | | | | | | | |
Collapse
|
32
|
Chetty U, Jack W, Dillon P, Tyler C, Prescott R. Axillary surgery in patients with breast cancer being treated by breast conservation: A randomised trial of node sample or axillary clearance. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80180-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Venizelos B, Chan P, Lambah A, Chiarello M, Chetty U, Dixon J. Morbidity following immediate breast reconstruction (IBR) after mastectomy. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80108-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
|
35
|
Thompson AM, Crichton DN, Elton RA, Clay MF, Chetty U, Steel CM. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up. Br J Cancer 1998; 77:797-800. [PMID: 9514060 PMCID: PMC2149971 DOI: 10.1038/bjc.1998.129] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Molecular and immunohistochemical studies of genetic events on chromosome 17p were prospectively compared with conventional clinical and pathological parameters and disease behaviour at a minimum of 72 months follow-up. In a series of 91 patients with primary operable breast cancer, 37 out of 91 (41%) patients had disease relapse and 23 out of 91 (25%) had died during the follow-up period. Allelic imbalance at the YNZ22 locus (17p13.3), demonstrated in 33 out of 63 (52%) informative patients, was significantly associated with disease recurrence (P < 0.01, 2 d.f. Cox analysis) and showed a trend towards impaired survival (P = 0.08, 2 d.f. Cox analysis) after a mean follow-up of 84 months for survivors. By contrast, p53 mutation (in 10 out of 60, 17% of cancers), p53 allelic imbalance (in 23 out of 56, 41% informative patients), p53 mRNA expression (in 47 out of 87, 54% patients), p53 mRNA overexpression (in 24 out of 87, 28%) or p53 protein expression (detected in 25/76, 32%) were not associated with disease behaviour. There was no significant association between allelic imbalance at YNZ22 and any abnormality of p53 DNA, RNA or protein. Allelic imbalance at 17p13.3 (YNZ22) serves as a marker of poor prognosis in breast cancer. As yet unidentified genes on 17p13.3, distinct from and telomeric to p53, are therefore likely to be of clinical importance in breast cancer.
Collapse
Affiliation(s)
- A M Thompson
- Department of Surgery, Ninewells Hospital and Medical School, Dundee, UK
| | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Abstract
Recent worldwide press and media speculation that silicone implants may be linked to an increased incidence of breast cancer, other cancers, and connective tissue diseases-particularly systemic sclerosis-is a current cause for concern to the medical profession and public alike. We conducted a cross-sectional study of the prevalence of connective tissue diseases, as well as signs and symptoms associated with these conditions, in women who had received a silicone gel-filled breast implant for either breast augmentation or breast reconstruction following mastectomy for breast cancer compared with women without implants in South East Scotland. We compared 317 patients who had had a silicone gel-filled breast implant inserted with matched controls. We found no increased incidence of antinuclear antibodies or rheumatoid factor in the study groups. We detected one case of rheumatoid arthritis in the reconstruction group and one in matched controls, but no cases of any other connective tissue disease. No cases were found among the augmentation patients or their controls. No differences were found in symptoms or physical signs of connective tissue diseases between the study patients and their controls. This study has failed to find any case for a link between silicone gel-filled breast implants and connective tissue diseases.
Collapse
Affiliation(s)
- A J Park
- Department of Plastic Surgery, St. John's Hospital, the Information and Statistics Division, National Health Service in Scotland, Livingston
| | | | | | | | | |
Collapse
|
38
|
Thompson AM, Elton RA, Hawkins RA, Chetty U, Steel CM. PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer. Br J Cancer 1998; 77:492-6. [PMID: 9472649 PMCID: PMC2151284 DOI: 10.1038/bjc.1998.78] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Expression of pS2, an oestrogen-regulated gene, has been associated with a good short-term prognosis and response to endocrine therapy. The aim of this study was to determine whether expression of mRNA for the pS2 gene in breast cancer could contribute useful information on disease behaviour and survival at medium-term follow-up. Northern blotting was used to detect pS2 messenger ribonucleic acid (mRNA) in the primary tumour tissue from each of 90 patients with breast cancer. Axillary node status was established by sampling or clearance, oestrogen receptor concentration by enzyme immunosorbant assay and follow-up was continued for at least 6 years or until death. At 83 months mean follow-up, 29 of 90 (32%) patients had recurrent disease and, of these, 18 (20%) had died from breast cancer. pS2 mRNA expression, present in 26 of 90 (29%) cancers, was associated with freedom from disease recurrence (P = 0.026) and was significantly associated with survival at a minimum of 6 years follow-up (P < 0.001). Pathological node status and tumour size were also significantly associated with disease recurrence (P < 0.001 and P = 0.002 respectively) and inversely with survival (P < 0.001 and P < 0.001 respectively). After multiple Cox regression analysis, pS2 expression was still a significant predictor of recurrence (but not survival) after adjusting for node status and tumour size; oestrogen receptor was an independent predictor of survival. The combination of node status and pS2 expression discriminated patients with particularly good prognosis (node negative, pS2 positive: no mortality at 6 years) or poor prognosis (node positive, pS2 negative; 41% mortality at 6 years). Evaluation of pS2 expression in breast cancer at diagnosis may provide additional useful prognostic information to conventional staging.
Collapse
Affiliation(s)
- A M Thompson
- Department of Surgery, Ninewells Hospital and Medical School, Dundee, UK
| | | | | | | | | |
Collapse
|
39
|
Thompson A, Clay M, Crichton D, Elton R, Chetty U, Steel C. 0-65. Allelic imbalance at chromosome 17p13.3(YNZ22) and poor prognosis in breast cancer. Breast 1997. [DOI: 10.1016/s0960-9776(97)90646-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
40
|
Chetty U, Jack W, Dillon P, Tyler C, Prescott R. 0-6. Axillary surgery in patients with breast cancer being treated by breast conservation: a randomised trial of node sampling and axillary clearance. Breast 1997. [DOI: 10.1016/s0960-9776(97)90587-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
41
|
Muir BB, Kirkpatrick AE, Anderson TJ, Lamb J, Walsh JS, Chetty U, Dixon JM, Anderson EC, Cunningham M. The impact of core-biopsy on pre-operative diagnosis rate of screen-detected breast cancers. Clin Radiol 1997; 52:566-7. [PMID: 9240717 DOI: 10.1016/s0009-9260(97)80342-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
42
|
Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C, Miller WR. The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res Treat 1997; 44:123-33. [PMID: 9232271 DOI: 10.1023/a:1005796915388] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Ki-S1, a marker of proliferation, and bcl-2, the gene product of which is an antagonist of apoptosis, have been measured in 51 ER-positive primary breast cancers before and during tamoxifen treatment and then related to clinical response. Both markers were detected in the majority of tumours before treatment and, quantitatively, initial expression of Bcl-2 protein, but not Ki-S1, was significantly related to the percentage reduction in tumour volume as assessed by ultrasound. Staining for both markers was lower in post treatment samples than in those taken prior to treatments, but concordant decreases in staining indices were seen in only 11 of the 51 tumours. The results demonstrate, using clinical material, that the response to tamoxifen may involve changes in proliferation and/or susceptibility to cell-death.
Collapse
Affiliation(s)
- J C Keen
- ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Cameron DA, Anderson ED, Levack P, Hawkins RA, Anderson TJ, Leonard RC, Forrest AP, Chetty U. Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer 1997; 76:1099-105. [PMID: 9376273 PMCID: PMC2228097 DOI: 10.1038/bjc.1997.514] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) were given preoperative systemic therapy. Initially, all women received hormone therapy, with CHOP (cyclophosphamide 1 g m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2) to a maximum of 2 mg and prednisolone 40 mg per day orally for 5 days) chemotherapy being administered to those who failed to respond by 3 months. After April 1987, first-line hormone therapy was only offered to women with oestrogen receptor (ER)-moderate/-rich (> 20 fmol mg(-1) protein) tumours, and CHOP was reserved for those women whose tumours failed to respond to hormone therapy and for those with ER-negative/-poor tumours. Response data have been published previously (Anderson et al, 1991). After a median follow-up of 7.5 years, there is no difference in survival between those women given initial hormone therapy and those given chemotherapy, with neither group having yet reached its median survival. The two key factors that predicted for a poor survival were the number of involved axillary nodes after preoperative systemic therapy (P < 0.00001) and a lack of response to preoperative therapy (P < 0.05). These data suggest that many women with ER-moderate/-rich tumours will have a good prognosis after preoperative hormone therapy alone. However, it is possible to identify, by their post-systemic therapy axillary node status, a group of women who still have an appalling prognosis after preoperative chemotherapy or hormone therapy.
Collapse
Affiliation(s)
- D A Cameron
- ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Cameron DA, Craig J, Gabra H, Lee L, MacKay J, Parker AC, Leonard RC, Anderson E, Anderson T, Chetty U, Dixon M, Hawkins A, Jack W, Kunkler I, Leonard R, Matheson L, Miller W. High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group. Br J Cancer 1996; 74:2013-7. [PMID: 8980406 PMCID: PMC2074804 DOI: 10.1038/bjc.1996.669] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Current treatments for metastatic breast cancer are not associated with significant survival benefits despite response rates of over 50%. High-dose therapy with autologous bone marrow transplantation (ABMT) has been investigated, particularly in North America, and prolonged survival in up to 25% of women has been reported, but with a significant treatment-related mortality. However, in patients with haematological malignancies undergoing autologous transplantation, haematopoietic reconstruction is significantly quicker and mortality lower than with ABMT, when peripheral blood progenitor cells (PBPCs) are used. In 32 women with metastatic breast cancer, we investigated the feasibility of PBPC mobilisation with high-dose cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) after 12 weeks' infusional induction chemotherapy and the subsequent efficacy of the haematopoietic reconstitution after conditioning with melphalan and either etoposide or thiotepa. PBPC mobilisation was successful in 28/32 (88%) patients, and there was a rapid post-transplantation haematopoietic recovery: median time to neutrophils > 0.5 x 10(9) l-1 was 14 days and to platelets > 20 x 10(9) l-1 was 10 days. There was no procedure-related mortality, and the major morbidity was mucositis (WHO grade 3-4) in 18/32 patients (56%). In a patient group of which the majority had very poor prognostic features, the median survival from start of induction chemotherapy was 15 months. Thus, PBPC mobilisation and support of high-dose chemotherapy is feasible after infusional induction chemotherapy for patients with metastatic breast cancer, although the optimum drug combination has not yet been determined.
Collapse
|
45
|
Abstract
Because of allegations linking silicone implants with cancer and connective tissue diseases and mounting media coverage, women with silicone breast implants are extremely concerned, despite the lack of evidence showing a link between silicone gel-filled breast implants and connective tissue diseases or cancer. To assess whether or not this group of women were satisfied with their operations, we sent all women who had silicone breast implants inserted in the south-east of Scotland between 1982 and 1991 a quality of life questionnaire. One hundred and two breast augmentation and 212 breast reconstruction patients replied. Not everyone answered every question. The majority of women in our study, 84% (79/94) and 91.8% (192/209) of augmented and reconstructed patients, respectively, stated that they were satisfied with their operations, although only about half were very satisfied. Although 91.2% (270/296) of all the women were aware of the allegations with 29.7% (88/296) concerned, only 3% (9/296) of all the women felt that there was cause for concern. It would appear that, although most women with silicone breast implants are aware of the accusations regarding silicone and systemic illnesses, the adverse publicity has only given a small number of them a cause for concern and the majority are satisfied with the outcome of their operation and perceive the benefits to outweigh the risks.
Collapse
Affiliation(s)
- A J Park
- Department of Plastic and Reconstructive Surgery, St. John's Hospital, Livingston, West Lothian, UK
| | | | | |
Collapse
|
46
|
Hawkins RA, Tesdale AL, Killen ME, Jack WJ, Chetty U, Dixon JM, Hulme MJ, Prescott RJ, McIntyre MA, Miller WR. Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer 1996; 74:1469-78. [PMID: 8912547 PMCID: PMC2074769 DOI: 10.1038/bjc.1996.567] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
In 215 patients with operable breast cancer (T1-T3, N0-1, M0) and no other or previous cancer, presenting to a single breast unit, sufficient tumour was available for the prospective determination of four putative biochemical markers of prognosis: oestrogen receptor (ER) activity, cathepsin D (cath D), epidermal growth factor receptor (EGFR) activity and cyclic AMP-binding proteins (c-AMP-b). There were significant inter-relationships between ER and EGFR (r = -0.26), c-AMP-b and cath D (r = +0.32) and ER and c-AMP-b (r = +0.14). After follow-up (median 36.2 months), a total of 55 recurrences (18 locoregional only) and 35 deaths were recorded. By univariate analysis, up to 10 of 18 biochemical, clinical and histopathological variables of potential prognostic value were significantly related to disease-free interval or death, but by multivariate analysis only oestrogen receptor concentration and node status contributed significantly to risk of both distant recurrence/death; in addition, tumour size made a small contribution to the risk for a distant recurrence only. Only two parameters, tumour grade and ER concentration, were significantly related to risk of locoregional recurrence by univariate analysis, but by multivariate analysis, only tumour grade was important. It is concluded that tumour ER concentration, axillary nodal status and tumour grade remain as the most important prognostic factors in the early years after presentation of operable breast cancer, with a minor influence of tumour size. At this time, the prognostic significance of quantitative measurements of ER concentration, carefully controlled for the quality of both assay and tumour specimen, is probably greater than is generally appreciated. We have yet to identify other factors, which add significantly to the short-term prognostic value of these key features.
Collapse
Affiliation(s)
- R A Hawkins
- University Department of Surgery, Royal Infirmary NHS Trust, Edinburgh
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Because little or no information exists about the life span of silicone implants, there is a need for a non-invasive and sensitive diagnostic tool for assessing their integrity. It is extremely difficult to diagnose rupture of these implants clinically. The aims of this study were to assess how many of our patients--in particular asymptomatic women--had ruptured implants and whether or not ultrasound was an effective tool in excluding rupture and reassuring anxious patients. All patients in the south east of Scotland who had a silicone gel-filled breast implant inserted between the years 1982-1991 were invited to take part in an investigation into morbidity due to silicone implants. We screened 307 asymptomatic patients with 385 implants and only found one patient with a ruptured silicone implant. One other patient had a ruptured saline implant and one implant was found to have leaked. We found ultrasound to be a quick, reliable, cheap and safe method of screening for implant rupture which can be used to reassure an anxious patient that her implants are intact.
Collapse
Affiliation(s)
- A J Park
- Department of Plastic Surgery, St. John's Hospital, Livingston, UK
| | | | | | | | | |
Collapse
|
48
|
Abstract
A prospective study of 14,225 patients has been undertaken to determine the inter-relationship between periductal mastitis and duct ectasia and to establish whether there is an association between smoking and either of these two conditions. Periductal mastitis affected women at a younger age than did duct ectasia. Of 139 patients with the clinical syndrome of periductal mastitis, 97 (70 per cent) had a past history of previous periductal mastitis, compared with only one (1 per cent) of 186 patients with the clinical syndrome of duct ectasia (P < 0.0001). There was a significant excess of smokers in patients with clinically (124 (89 per cent) of 139) and pathologically (71 (91 per cent) of 78) diagnosed periductal mastitis compared with age-matched controls (both P < 0.001), but there was no such excess in those with clinically (52 (28 per cent) of 186) or pathologically (15 (23 per cent) of 64) diagnosed duct ectasia. These data suggest that periductal mastitis and duct ectasia are separate conditions which affect different age groups, have different aetiologies, and should now be considered as separate entities.
Collapse
Affiliation(s)
- J M Dixon
- University Department of Surgery, Edinburgh Royal Infirmary, UK
| | | | | | | |
Collapse
|
49
|
Dixon JM, Dobie V, Lamb J, Walsh JS, Chetty U. Assessment of the acceptability of conservative management of fibroadenoma of the breast. Br J Surg 1996. [DOI: 10.1002/bjs.1800830238] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
50
|
Dixon JM, Dobie V, Lamb J, Walsh JS, Chetty U. Assessment of the acceptability of conservative management of fibroadenoma of the breast. Br J Surg 1996; 83:264-5. [PMID: 8689184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
A prospective study was performed in 202 patients with 219 fibroadenomas, diagnosed by a combination of clinical examination, ultrasonography and fine-needle aspiration cytology. Patients were given the choice of excision or conservative management with regular monitoring by ultrasonography. Sixteen patients with 18 fibroadenomas opted for excision and all 18 lesions were histologically confirmed as fibroadenomas. A further 152 patients with 163 fibroadenomas were observed for a minimum period of 2 years; 13 fibroadenomas increased significantly in size (all 13 were excised and confirmed histologically as fibroadenomas), 19 decreased significantly in size, 42 resolved and the remaining 89 showed no change in size. Conservative management of fibroadenomas in patients under the age of 40 is safe and acceptable to the majority of women.
Collapse
Affiliation(s)
- J M Dixon
- Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
| | | | | | | | | |
Collapse
|